...
机译:施用后体内聚乙二醇化NELL-1的药代动力学和成骨潜力
Univ Calif Los Angeles Sch Dent Div Growth &
Dev Los Angeles CA 90095 USA;
Univ Calif Los Angeles Dept Bioengn Los Angeles CA 90095 USA;
Univ Calif Los Angeles Dept Craniofacial Res Inst Los Angeles CA 90095 USA;
Univ Calif Los Angeles Sch Dent Div Growth &
Dev Los Angeles CA 90095 USA;
Univ Calif Los Angeles Sch Dent Div Growth &
Dev Los Angeles CA 90095 USA;
Univ Calif Los Angeles Sch Dent Div Growth &
Dev Los Angeles CA 90095 USA;
Univ Calif Los Angeles Sch Dent Div Growth &
Dev Los Angeles CA 90095 USA;
CHA Univ CHA Bundang Med Ctr Dept Orthopaed Surg Pocheon Si Gyeonggi Do South Korea;
Univ Calif Los Angeles Sch Dent Div Growth &
Dev Los Angeles CA 90095 USA;
Univ Calif Los Angeles Dept Bioengn Los Angeles CA 90095 USA;
Univ Calif Los Angeles Sch Dent Div Growth &
Dev Los Angeles CA 90095 USA;
Univ Calif Los Angeles Dept Orthopaed Surg Los Angeles CA 90095 USA;
NELL-1; PEGylation; Pharmacokinetics; Osteogenesis; Osteoporosis;
机译:施用后体内聚乙二醇化NELL-1的药代动力学和成骨潜力
机译:在小鼠模型中全身施用Fospeg(R)-聚乙二醇化脂质体mTHPC制剂后的药代动力学和生物分布研究
机译:原始文章-体内施用G9a抑制剂A366可降低骨髓源性间充质干细胞的成骨潜能
机译:含依托泊苷的聚乙二醇化脂质体的制备,表征,体内药代动力学和抑瘤特性
机译:腹膜内施用PEG化NELL-1对骨形成的功效。
机译:全身给药后体内PEG化NELL-1的药代动力学和成骨潜能
机译:全身施用后体内聚乙二醇化NELL-1的药代动力学和成骨潜力